Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of KX2-391 Ointment in Actinic Keratosis
NCT03575780Phase 1Completed
- Sponsor
- Athenex
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirbanibulin in actinic keratosis (AK), sponsored by Athenex. Primary endpoint: Amount of KX2-391 Ointment in the blood stream at 6 Days. Started Sep 2018; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03575780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575780.